HC Wainwright restated their neutral rating on shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) in a research note released on Thursday morning,Benzinga reports.
A number of other analysts have also recently weighed in on AVTX. Piper Sandler started coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an "overweight" rating and a $48.00 price target on the stock. BTIG Research initiated coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research note on Thursday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Avalo Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $35.33.
View Our Latest Stock Analysis on AVTX
Avalo Therapeutics Price Performance
Shares of NASDAQ:AVTX traded down $0.23 during trading on Thursday, reaching $7.43. 7,371 shares of the company's stock traded hands, compared to its average volume of 210,327. Avalo Therapeutics has a 12 month low of $4.60 and a 12 month high of $34.46. The company has a 50 day moving average of $7.45 and a 200-day moving average of $9.13.
Hedge Funds Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its position in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after acquiring an additional 3,754 shares during the period. Marshall Wace LLP bought a new position in shares of Avalo Therapeutics in the fourth quarter worth $114,000. Walleye Capital LLC acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at $145,000. Northern Trust Corp bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at about $168,000. Finally, Bank of Montreal Can acquired a new stake in Avalo Therapeutics in the fourth quarter worth about $446,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
See Also
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
